REG - N4 Pharma PLC - Result of AGM

N4 PharmaAnnouncement

23/05/2024 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW6939Pa&default-theme=true

RNS Number : 6939P  N4 Pharma PLC  23 May 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Result of Annual General Meeting

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that at its annual general meeting ("AGM"), held earlier
today, all resolutions were duly passed.

 

 

 Resolution                                                       For         For%    Against  Against%  Total       Witheld votes*
 Ordinary Resolution 1                                            20,612,844  99.93%  13,980   0.07%     20,626,824  296,841

 To receive the annual report and audited accounts for the year

 ended 31 December 2023
 Ordinary Resolution 2                                            20,605,744  99.32%  141,080  0.68%     20,746,824  176,841

 To re-elect Nigel Theobald as a Director of the Company
 Ordinary Resolution 3                                            20,605,744  99.32%  141,080  0.68%     20,746,824  176,841

 To re-elect David Templeton as a Director of the Company
 Ordinary Resolution 4                                            20,605,644  99.32%  140,980  0.68%     20,746,624  177,041

 To re-appoint Saffery Champness LLP as the Companyʼs auditor

 and to authorise the Directors to determine their remuneration
 Ordinary Resolution 5                                            20,559,085  99.10%  187,539  0.90%     20,746,624  177,041

 To authorise the Directors to allot shares
 Special Resolution 6                                             20,506,310  99.00%  207,439  1.00%     20,713,749  209,916

 To disapply pre-emption rights

 

*Please note a vote withheld is not a vote in law and is not counted in the
calculation of votes validly cast for or against a resolution.

 

For more information please contact:

 

 N4 Pharma plc                                                        investors.n4pharma.com (http://investors.n4pharma.com)

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 InvestorHub                                                          Sign up at investors.n4pharma.com (http://investors.n4pharma.com)

 Engage with us directly at N4 Pharma Investor Hub

                                                                      https://investors.n4pharma.com/link/Ky0AZe
                                                                      (https://investors.n4pharma.com/link/Ky0AZe)

 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at www.investors.n4pharma.com
(http://www.investors.n4pharma.com) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBBGDUIBDDGSX